Q1 2023 · 13F-HR
Boxer Capital, LLCholdings as filed
Filed 2023-05-15 · accession 0000895345-23-000296
$2.0M
Reported value
75
Positions
2023-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74349U108 | — | Prometheus Biosciences Inc | $203,640 | 10.0% | 1,897,500 | Common | SOLE |
| 75615P103 | — | Reata Pharmaceuticals Inc | $111,832 | 5.49% | 1,230,004 | Common | SOLE |
| 07725L102 | ONC | BeiGene Ltd | $107,765 | 5.29% | 500,000 | Common | SOLE |
| 803607100 | SRPT | Sarepta Therapeutics Inc | $106,818 | 5.25% | 775,000 | Common | SOLE |
| 03753U106 | APLSUSD | Apellis Pharmaceuticals Inc | $103,953 | 5.11% | 1,576,000 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $103,625 | 5.09% | 6,448,359 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines Inc | $101,461 | 4.98% | 4,684,264 | Common | SOLE |
| 85205L107 | SWTXUSD | Springworks Therapeutics Inc | $88,070 | 4.33% | 3,421,541 | Common | SOLE |
| 60468T105 | MRTXEUR | Mirati Therapeutics Inc | $74,360 | 3.65% | 2,000,000 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $73,899 | 3.63% | 2,100,000 | Common | SOLE |
| 03237H101 | AMLX | Amylyx Pharmaceuticals Inc | $61,145 | 3.00% | 2,084,000 | Common | SOLE |
| 78667J108 | SG7 | Sage Therapeutics Inc | $45,904 | 2.26% | 1,094,000 | Common | SOLE |
| 81181C104 | — | Seagen Inc | $40,494 | 1.99% | 200,000 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc | $35,726 | 1.76% | 2,169,132 | Common | SOLE |
| N5749R100 | 2GH | Merus N V | $34,960 | 1.72% | 1,900,000 | Common | SOLE |
| 92686J106 | VKTX | Viking Therapeutics Inc | $33,300 | 1.64% | 2,000,000 | Common | SOLE |
| 282559103 | ETNBGBP | 89Bio Inc | $31,983 | 1.57% | 2,100,000 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $31,813 | 1.56% | 831,495 | Common | SOLE |
| 670703107 | NUVL | Nuvalent Inc | $31,574 | 1.55% | 1,210,192 | Common | SOLE |
| 45166A102 | IDYA | Ideaya Biosciences Inc | $30,245 | 1.49% | 2,202,812 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics Inc | $29,317 | 1.44% | 2,154,058 | Common | SOLE |
| 92332V107 | VTYXUSD | Ventyx Biosciences Inc | $28,475 | 1.40% | 850,000 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio Inc | $28,288 | 1.39% | 1,300,000 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $28,138 | 1.38% | 7,123,642 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $26,123 | 1.28% | 1,432,200 | Common | SOLE |
| 03152W109 | AM6 | Amicus Therapeutics Inc | $25,784 | 1.27% | 2,325,000 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals Inc | $25,113 | 1.23% | 1,466,051 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $24,672 | 1.21% | 400,000 | Common | SOLE |
| 07987C204 | BLU | Bellus Health Inc New | $23,040 | 1.13% | 3,200,000 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $22,638 | 1.11% | 3,705,133 | Common | SOLE |
| 30161Q104 | EXEL | Exelixis Inc | $22,322 | 1.10% | 1,150,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $21,474 | 1.05% | 600,000 | Common | SOLE |
| 46583P102 | — | Iveric Bio Inc | $20,072 | 0.99% | 825,000 | Common | SOLE |
| 75082Q105 | — | Rain Oncology Inc | $18,767 | 0.92% | 2,147,212 | Common | SOLE |
| 730541109 | — | Point Biopharma Global Inc | $18,175 | 0.89% | 2,500,000 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $17,212 | 0.85% | 1,121,327 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals I | $15,910 | 0.78% | 1,189,943 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics Inc | $15,563 | 0.76% | 710,644 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals Inc | $15,091 | 0.74% | 3,163,795 | Common | SOLE |
| G72800108 | PRTA | Prothena Corp PLC | $14,541 | 0.71% | 300,000 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $12,969 | 0.64% | 1,650,000 | Common | SOLE |
| 230031106 | CGEM | Cullinan Oncology Inc | $10,988 | 0.54% | 1,074,082 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics Inc | $10,877 | 0.53% | 1,224,892 | Common | SOLE |
| 04351P101 | ASNDUSD | Ascendis Pharma A/S | $10,186 | 0.50% | 95,000 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Hldg Inc | $7,528 | 0.37% | 200,000 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $6,008 | 0.30% | 1,054,000 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $5,665 | 0.28% | 525,000 | Common | SOLE |
| 75382E109 | — | Rapt Therapeutics Inc | $5,505 | 0.27% | 300,000 | Common | SOLE |
| G6882C106 | — | Panacea Acquisition Corp II | $5,110 | 0.25% | 500,000 | Common | SOLE |
| 68572M106 | OBIO | Orchestra Biomed Hldgs Inc | $4,893 | 0.24% | 250,000 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals PLC | $4,817 | 0.24% | 1,251,137 | Common | SOLE |
| 901384107 | TSVT* | 2Seventy Bio Inc | $4,690 | 0.23% | 459,836 | Common | SOLE |
| 816212104 | SELBUSD | Selecta Biosciences Inc | $4,565 | 0.22% | 3,284,072 | Common | SOLE |
| 12674W109 | CABA | Cabaletta Bio Inc | $4,466 | 0.22% | 540,000 | Common | SOLE |
| 38341P102 | GOSS | Gossamer Bio Inc | $4,205 | 0.21% | 3,336,928 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc | $3,985 | 0.20% | 699,047 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics I | $3,808 | 0.19% | 2,014,858 | Common | SOLE |
| 49705R105 | KNTEUSD | Kinnate Biopharma Inc | $3,188 | 0.16% | 510,000 | Common | SOLE |
| 88369M101 | — | Theseus Pharmaceuticals Inc | $3,108 | 0.15% | 350,000 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics Inc | $2,850 | 0.14% | 500,000 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $2,755 | 0.14% | 130,000 | Common | SOLE |
| 59935V107 | MIST | Milestone Pharmaceuticals In | $2,754 | 0.14% | 698,861 | Common | SOLE |
| 04965G109 | BCELUSD | Atreca Inc | $2,511 | 0.12% | 2,202,333 | Common | SOLE |
| 23306J101 | — | DBV Technologies S A | $2,451 | 0.12% | 1,450,000 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio Inc | $2,350 | 0.12% | 570,417 | Common | SOLE |
| 62921N105 | NGMUSD | NGM Biopharmaceuticals Inc | $2,040 | 0.10% | 500,000 | Common | SOLE |
| 26886C107 | — | EQRx Inc | $1,940 | 0.10% | 1,000,000 | Common | SOLE |
| 09077B104 | BCABGBP | BioAtla Inc | $1,839 | 0.09% | 686,347 | Common | SOLE |
| 589492107 | MREO | Mereo Biopharma Group PLC | $1,591 | 0.08% | 2,250,000 | Common | SOLE |
| 98973P101 | — | Alaunos Therapeutics Inc | $945 | 0.05% | 1,500,000 | Common | SOLE |
| 55279B202 | — | MEI Pharma Inc | $667 | 0.03% | 2,913,091 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics Inc | $655 | 0.03% | 209,227 | Common | SOLE |
| 92536C103 | VERUEUR | Veru Inc | $403 | 0.02% | 347,300 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc | $32 | 0.00% | 266,666 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen Inc | $4 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.